CIK: 0000310158
Total reported value
$349.4M
Reporting period: 2026-03-31 · Number of holdings: 14
Merck & Co., Inc. disclosed 14 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $349.4M and a quarterly turnover rate of 39.8%.
Browse other institutions with $100M to $1B AUMBrowse other institutions starting with "M"
Merck & Co., Inc.'s disclosed holdings carry a Herfindahl concentration index of 0.222 — mathematically equivalent to about 5 equally-sized positions, well below its 14 actual disclosed holdings. That gap points to a strategy built around a small core of high-conviction bets rather than broad diversification.
Position sizes vary widely across the portfolio (a coefficient of variation of 1.51), with a handful of outsized bets alongside many smaller positions.
Recent activity leans toward initiating meaningfully larger new positions than it adds to existing ones (a 3.4 percentage-point tilt) — a pattern consistent with a more contrarian, new-idea-driven approach.
Sector classification currently covers about 34% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Trim PSNL
0.0% -$22.3M
Add MRNA
0.0% $49.2M
Trim KYMR
0.0% $4.2M
Trim EVAXUSD
0.0% -$1.3M
Add STRO
0.0% $3.6M
Trim VRDN
0.0% -$1.1M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | MRNA | Moderna INC | Stock-Healthcare | 33.56% | +8.92% | — | |
| 2 | PSNL | Personalis INC | Stock-Other | 25.60% | -14.87% | — | |
| 3 | KYMR | Kymera Therapeutics INC | Stock-Other | 18.40% | -3.35% | — | |
| 4 | ✓ | Stock-Other | 6.28% | -0.19% | — | ||
| 5 | EIKN | Eikon Therapeutics INC | Stock-Other | 5.05% | +5.05% | NEW | |
| 6 | AKTS | Aktis Oncology INC | Stock-Other | 4.88% | +4.88% | NEW | |
| 7 | ALEC | Alector INC | Stock-Other | 2.18% | +0.18% | — | |
| 8 | STRO | Sutro Biopharma, Inc. | Stock-Other | 1.94% | +0.80% | — | |
| 9 | EVAXUSD | Evaxion Biotech A/s | Stock-Other | 1.29% | -0.81% | — | |
| 10 | VRDN | Viridian Therapeutics INC | Stock-Other | 0.52% | -0.53% | — | |
| 11 | XLO | Xilio Therapeutics INC | Stock-Other | 0.26% | +0.26% | NEW | |
| 12 | CARM | Carisma Therapeutics INC | Stock-Other | 0.01% | -0.01% | — | |
| 13 | NEUP | Neuphoria Therapeutics INC | Stock-Other | 0.01% | — | — | |
| 14 | HURA | Tuhura Biosciences INC | Stock-Other | 0.01% | +0.01% | +39.39% |
Performance for Q3 2026
+102.2%
Performance Last 4 Quarters
+173%
Based on 57% of reported portfolio value with available pricing
Merck & Co., Inc.'s most significant position changes for 2026-03-31: New buy: Eikon Therapeutics INC (EIKN); New buy: Aktis Oncology INC (AKTS); Sold out: Xilio Therapeutics INC; New buy: Xilio Therapeutics INC (XLO); Add: Tuhura Biosciences INC (HURA) — shares +39.39%.
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | MRNA | Moderna INC | +8.9% | — | Unchanged |
| 2 | STRO | Sutro Biopharma, Inc. | +0.8% | — | Unchanged |
| 3 | ALEC | Alector INC | +0.2% | — | Unchanged |
| 4 | HURA | Tuhura Biosciences INC | 0% | +39.39% | Add |
| 5 | NEUP | Neuphoria Therapeutics INC | — | — | Unchanged |
| 6 | CARM | Carisma Therapeutics INC | 0% | — | Unchanged |
| 7 | ✓ | -0.2% | — | Unchanged | |
| 8 | VRDN | Viridian Therapeutics INC | -0.5% | — | Unchanged |
| 9 | EVAXUSD | Evaxion Biotech A/s | -0.8% | — | Unchanged |
| 10 | KYMR | Kymera Therapeutics INC | -3.4% | — | Unchanged |
| 11 | PSNL | Personalis INC | -14.9% | — | Unchanged |
| 12 | EIKN | Eikon Therapeutics INC | — | NEW | New buy |
| 13 | AKTS | Aktis Oncology INC | — | NEW | New buy |
| 14 | ✓ | Xilio Therapeutics INC | — | EXIT | Sold out |
| 15 | XLO | Xilio Therapeutics INC | — | NEW | New buy |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2026-03-31 | 2026-05-13 | 13F-HR | View on EDGAR |
| 2025-12-31 | 2026-02-17 | 13F-HR | View on EDGAR |
| 2025-09-30 | 2025-11-12 | 13F-HR | View on EDGAR |
| 2025-06-30 | 2025-08-13 | 13F-HR | View on EDGAR |
| 2025-03-31 | 2025-05-14 | 13F-HR | View on EDGAR |
| 2024-12-31 | 2025-02-14 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0001512779
Total reported value
$349.5M
278 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001004140
Total reported value
$349.5M
112 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001802474
Total reported value
$349.4M
865 stks
2026-03-31
AUM within 0.0% of this institution
Institutions with overlapping top holdings
CIK 0001056807
Total reported value
$3.1B
41 stks
2026-03-31
1 of the top 5 holdings overlap, including Kymera Therapeutics INC
CIK 0001223025
Total reported value
$426.7M
242 stks
2022-12-31
Stale — no recent filing
1 of the top 5 holdings overlap, including Moderna INC
CIK 0001400240
Total reported value
$1.2B
7 stks
2026-03-31
1 of the top 5 holdings overlap, including Moderna INC